STAT3 and prostate cancer: Targeting this pathway has emerged as a promising strategy to overcome resistance, with preclinical studies showing that inhibitors of STAT3/JAK2, such as AG490, can reduce STAT3-mediated AR activation and hinder prostate cancer cell growth [107,108].